Coleman et al. conducted a comprehensive analysis of key clinical trials in NSCLC and reported that MET amplification was identified as a mechanism of resistance in 7–15% of patients who experienced treatment failure with first-line osimertinib and in 10–22% following second-line osimertinib [26]. Here, MET is linked to non-small cell lung carcinoma.